
- /
- Supported exchanges
- / US
- / DRRX.NASDAQ
Durect Corporation (DRRX NASDAQ) stock market data APIs
Durect Corporation Financial Data Overview
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. As of September 11, 2025, DURECT Corporation operates as a subsidiary of Bausch Health Americas, Inc.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Durect Corporation (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Durect Corporation data using free add-ons & libraries
Get Durect Corporation Fundamental Data
Durect Corporation Fundamental data includes:
- Net Revenue: 1 657 K
- EBITDA: -15 231 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.12
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Durect Corporation News

Bausch Health Companies Inc. (BHC) Acquires DURECT in $413 Million Deal to Tackle Alcoholic Hepatitis
In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Bausch Health Companies is one of them. Bausch Health Companies Inc. (NYSE:BHC), a global specialty pharmaceuti...


Bausch Health Completes $63 Mln Acquisition Of DURECT, Adds Breakthrough AH Therapy
(RTTNews) - Bausch Health Companies Inc. has successfully completed its tender offer to acquire DURECT Corporation (DRRX) for $1.75 per share in cash, totaling approximately $63 million upfront. The ...

Bausch Health Completes US$63 Million Durect Acquisition, Adds Breakthrough Hepatitis Therapy to Pipeline
Bausch Health Companies (BHC.TO) Thursday said it completed its acquisition of Durect for US$1.75 pe PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LA...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.